Patient characteristics at enrollment
Characteristic . | Total . | MP . | M-DEX . | DEX . | DEX-IFN . | P* . |
|---|---|---|---|---|---|---|
| No. patients | 488 | 122 | 118 | 127 | 121 | — |
| Female sex | 239 (49) | 53 (43) | 63 (53) | 63 (50) | 60 (50) | .48 |
| Age | ||||||
| Median age, y | 70 (67-72) | 70 (68-72) | 69 (68-72) | 70 (67-73) | 69 (67-72) | .31 |
| No. older than 70 y | 200 (41) | 55 (45) | 45 (38) | 55 (43) | 45 (37) | .52 |
| Stage | ||||||
| I | 52 (11) | 14 (11) | 13 (11) | 16 (13) | 9 (7) | — |
| II | 139 (28) | 43 (35) | 31 (26) | 35 (28) | 30 (25) | — |
| III | 293 (60) | 65 (53) | 72 (61) | 75 (59) | 81 (67) | — |
| PCL | 4 (1) | 0 | 2 (2) | 1 (1) | 1 (1) | — |
| B substage | 43 (9) | 13 (11) | 9 (8) | 7 (6) | 14 (12) | .32 |
| M component | ||||||
| IgG | 292 (60) | 71 (58) | 71 (60) | 82 (65) | 68 (57) | — |
| IgA | 132 (27) | 36 (30) | 29 (25) | 34 (27) | 33 (28) | — |
| Bence Jones | 44 (9) | 13 (11) | 12 (10) | 6 (5) | 13 (11) | — |
| Other | 19 (4) | 2 (2) | 6 (5) | 5 (4) | 6 (5) | — |
| Kappa light chain† | 289 (62) | 78 (65) | 67 (60) | 74 (61) | 70 (61) | .85 |
| Bone lesions | ||||||
| None | 94 (19) | 26 (21) | 27 (23) | 22 (17) | 19 (16) | — |
| Diffuse | 217 (45) | 46 (38) | 53 (45) | 61 (48) | 57 (47) | — |
| Others | 176 (36) | 50 (41) | 38 (32) | 43 (34) | 45 (37) | — |
| Hemoglobin level, g/dL | 10.8 (9.4-12.0) | 10.8 (9.2-11.9) | 10.7 (9.5-12.0) | 11.0 (9.7-12.1) | 10.5 (9.1-11.9) | .17 |
| Platelet count, × 109/L | 232 (178-292) | 223 (171-284) | 245 (194-310) | 232 (180-292) | 231 (181-281) | .27 |
| Presence of circulating plasma cells | 35 (7) | 6 (5) | 5 (4) | 12 (10) | 12 (10) | .19 |
| Serum β2-microglobulin level, g/L‡ | 3.7 (2.6-5.5) | 3.7 (2.6-5.9) | 3.5 (2.4-5.2) | 3.7 (2.7-5.5) | 3.7 (2.8-5.5) | .61 |
| Creatinine level, mg/L | 10.7 (9.0-13.0) | 10.4 (8.9-12.7) | 10.4 (9.0-13.0) | 10.2 (8.6-13.0) | 11.4 (9.4-14.0) | .11 |
| Serum calcium level, mg/L | 95 (90-101) | 95 (90-100) | 95 (90-100) | 95 (90-102) | 96 (91-105) | .37 |
| Serum albumin level, g/L | 38.0 (34.0-42.0) | 38.0 (34.3-42.0) | 39.0 (35.0-42.0) | 37.0 (32.3-42.8) | 37.0 (34.5-42.0) | .43 |
| LDH level, UI/L§ | 295 (219-399) | 291 (221-426) | 339 (214-410) | 301 (225-387) | 285 (219-365) | .68 |
| CRP level, mg/L∥ | 5 (3-13) | 5 (3-15) | 5 (3-15) | 5 (3-13) | 5 (3-12) | .99 |
Characteristic . | Total . | MP . | M-DEX . | DEX . | DEX-IFN . | P* . |
|---|---|---|---|---|---|---|
| No. patients | 488 | 122 | 118 | 127 | 121 | — |
| Female sex | 239 (49) | 53 (43) | 63 (53) | 63 (50) | 60 (50) | .48 |
| Age | ||||||
| Median age, y | 70 (67-72) | 70 (68-72) | 69 (68-72) | 70 (67-73) | 69 (67-72) | .31 |
| No. older than 70 y | 200 (41) | 55 (45) | 45 (38) | 55 (43) | 45 (37) | .52 |
| Stage | ||||||
| I | 52 (11) | 14 (11) | 13 (11) | 16 (13) | 9 (7) | — |
| II | 139 (28) | 43 (35) | 31 (26) | 35 (28) | 30 (25) | — |
| III | 293 (60) | 65 (53) | 72 (61) | 75 (59) | 81 (67) | — |
| PCL | 4 (1) | 0 | 2 (2) | 1 (1) | 1 (1) | — |
| B substage | 43 (9) | 13 (11) | 9 (8) | 7 (6) | 14 (12) | .32 |
| M component | ||||||
| IgG | 292 (60) | 71 (58) | 71 (60) | 82 (65) | 68 (57) | — |
| IgA | 132 (27) | 36 (30) | 29 (25) | 34 (27) | 33 (28) | — |
| Bence Jones | 44 (9) | 13 (11) | 12 (10) | 6 (5) | 13 (11) | — |
| Other | 19 (4) | 2 (2) | 6 (5) | 5 (4) | 6 (5) | — |
| Kappa light chain† | 289 (62) | 78 (65) | 67 (60) | 74 (61) | 70 (61) | .85 |
| Bone lesions | ||||||
| None | 94 (19) | 26 (21) | 27 (23) | 22 (17) | 19 (16) | — |
| Diffuse | 217 (45) | 46 (38) | 53 (45) | 61 (48) | 57 (47) | — |
| Others | 176 (36) | 50 (41) | 38 (32) | 43 (34) | 45 (37) | — |
| Hemoglobin level, g/dL | 10.8 (9.4-12.0) | 10.8 (9.2-11.9) | 10.7 (9.5-12.0) | 11.0 (9.7-12.1) | 10.5 (9.1-11.9) | .17 |
| Platelet count, × 109/L | 232 (178-292) | 223 (171-284) | 245 (194-310) | 232 (180-292) | 231 (181-281) | .27 |
| Presence of circulating plasma cells | 35 (7) | 6 (5) | 5 (4) | 12 (10) | 12 (10) | .19 |
| Serum β2-microglobulin level, g/L‡ | 3.7 (2.6-5.5) | 3.7 (2.6-5.9) | 3.5 (2.4-5.2) | 3.7 (2.7-5.5) | 3.7 (2.8-5.5) | .61 |
| Creatinine level, mg/L | 10.7 (9.0-13.0) | 10.4 (8.9-12.7) | 10.4 (9.0-13.0) | 10.2 (8.6-13.0) | 11.4 (9.4-14.0) | .11 |
| Serum calcium level, mg/L | 95 (90-101) | 95 (90-100) | 95 (90-100) | 95 (90-102) | 96 (91-105) | .37 |
| Serum albumin level, g/L | 38.0 (34.0-42.0) | 38.0 (34.3-42.0) | 39.0 (35.0-42.0) | 37.0 (32.3-42.8) | 37.0 (34.5-42.0) | .43 |
| LDH level, UI/L§ | 295 (219-399) | 291 (221-426) | 339 (214-410) | 301 (225-387) | 285 (219-365) | .68 |
| CRP level, mg/L∥ | 5 (3-13) | 5 (3-15) | 5 (3-15) | 5 (3-13) | 5 (3-12) | .99 |
Data are presented as no. (%) for qualitative characteristics, and as median (interquartile range) for quantitative characteristics.
PCL indicates plasma cell leukemia; —, not applicable; and LDH, lactico dehydrogenase.
Chi2 and Kruskal-Wallis tests for qualitative and quantitative characteristics, respectively
n = 468
n = 447
n = 435
n = 449